Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABBV

Abbvie Inc

Sep 12 • 04:00PM ET

218.34

-1.88 -0.85 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: JNJ PFE MRK LLY BMY GILD AMGN REGN VRTX BIIB

| Held by: VTI VOO SPY IVV SCHD VTV XLV VIG IWF VYM

Scroll to Statements

Index	S&P 500	P/E	103.91	EPS (ttm)	2.10	Insider Own	0.11%	Shs Outstand	1.77B	Perf Week	2.72%
Market Cap	385.71B	Forward P/E	15.33	EPS next Y	14.24	Insider Trans	-6.37%	Shs Float	1.76B	Perf Month	8.37%
Enterprise Value	449.77B	PEG	6.57	EPS next Q	3.26	Inst Own	74.34%	Short Float	0.87%	Perf Quarter	13.47%
Income	3.72B	P/S	6.61	EPS this Y	18.87%	Inst Trans	0.11%	Short Ratio	2.79	Perf Half Y	3.21%
Sales	58.33B	P/B	-	EPS next Y	18.38%	ROA	2.67%	Short Interest	15.40M	Perf YTD	22.87%
Book/sh	-0.10	P/C	59.64	EPS next 5Y	15.82%	ROE	112.90%	52W High	221.76 -1.54%	Perf Year	9.53%
Cash/sh	3.66	P/FCF	21.15	EPS past 3/5Y	-28.18% -14.67%	ROIC	5.93%	52W Low	163.81 33.29%	Perf 3Y	57.41%
Dividend Est.	6.54 (2.99%)	EV/EBITDA	16.81	Sales past 3/5Y	0.08% 11.11%	Gross Margin	70.97%	Volatility	1.60% 1.54%	Perf 5Y	137.66%
Dividend TTM	6.47 (2.96%)	EV/Sales	7.71	EPS Y/Y TTM	-29.75%	Oper. Margin	31.61%	ATR (14)	3.76	Perf 10Y	254.56%
Dividend Ex-Date	Oct 15, 2025	Quick Ratio	0.61	Sales Y/Y TTM	6.05%	Profit Margin	6.38%	RSI (14)	71.06	Recom	1.90
Dividend Gr. 3/5Y	5.81% 7.46%	Current Ratio	0.74	EPS Q/Q	-31.76%	SMA20	3.71%	Beta	0.50	Target Price	219.44
Payout	263.15%	Debt/Eq	-	Sales Q/Q	6.65%	SMA50	9.24%	Rel Volume	0.80	Prev Close	220.22
Employees	55000	LT Debt/Eq	-	Earnings	Jul 31 BMO	SMA200	14.42%	Avg Volume	5.51M	Price	218.34
IPO	Dec 10, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.12% 2.62%	Trades		Volume	4,418,482	Change	-0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-25	Resumed	Piper Sandler	Overweight	$231
Aug-07-25	Upgrade	Daiwa Securities	Neutral → Outperform	$214
May-14-25	Downgrade	Citigroup	Buy → Neutral	$205
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$210
Dec-10-24	Resumed	BofA Securities	Neutral	$191
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral	$180
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform	$206
Nov-15-24	Initiated	Wolfe Research	Outperform	$205
Nov-04-24	Upgrade	Argus	Hold → Buy
Oct-17-24	Initiated	Bernstein	Mkt Perform	$203
Jun-05-24	Upgrade	HSBC Securities	Hold → Buy	$185
May-17-24	Initiated	Cantor Fitzgerald	Overweight	$200
Jan-29-24	Upgrade	William Blair	Mkt Perform → Outperform
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Dec-11-23	Upgrade	Goldman	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Hold	$150
Oct-30-23	Upgrade	Barclays	Equal Weight → Overweight	$160 → $170
Oct-20-23	Resumed	UBS	Neutral	$157 → $150
Sep-29-23	Initiated	Raymond James	Outperform	$177
Jul-25-23	Initiated	William Blair	Mkt Perform

Show Previous Ratings

Today 06:42AM	3 No-Brainer Dividend Stocks to Buy in September (Motley Fool)
Sep-12-25 08:14PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
01:48PM	AbbVie Shares Hit Record High on Rinvoq Exclusivity Extension to 2037 (GuruFocus.com)
01:30PM	1 Green Flag for AbbVie (ABBV) Stock Right Now (Motley Fool)
12:11PM	Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most. (Barrons.com)
09:57AM	Loading…
09:57AM	AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. (Barrons.com)
09:21AM	AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock (Zacks)
09:18AM	Company News for Sep 12, 2025 (Zacks)
08:55AM	AbbVie settles litigation with all generic manufacturers of Rinvoq (TipRanks)
07:25AM	AbbVie extends Rinvoq exclusivity by four years after generics settlements (Pharmaceutical Technology)
04:46AM	The Best Stocks to Invest $50,000 In Right Now (Motley Fool)
Sep-11-25 06:48PM	Analyst Report: AbbVie Inc. (Morningstar Research)
03:43PM	Prescription Drug Ads Could Be Changing. These Stocks Could Get Hurt the Most. (Barrons.com)
02:10PM	Stocks to Watch Thursday: Warner Bros., Paramount, Opendoor, Alibaba (The Wall Street Journal)
01:30PM	Warren Buffett wouldnt worry about cash if he retired with just $1M heres why and how to copy his strategy (Moneywise)
12:45PM	Loading…
12:45PM	SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag (Zacks)
12:24PM	AbbVie shares hit record high as key immunology drug set for exclusivity until 2037 (Reuters)
12:17PM	AbbVie in Settlement With Generic Drugmakers on Rinvoq (The Wall Street Journal)
11:56AM	Why AbbVie (ABBV) Stock Is Trading Up Today (StockStory)
11:50AM	Why AbbVie Stock Is Jumping Today (Motley Fool)
11:47AM	AbbVie Stock Breaks Out As Its Cash Cow Lives To Fight Another Day (Investor's Business Daily)
10:27AM	AbbVie stock rises after securing patent protection for RINVOQ until 2037 (Investing.com)
09:00AM	AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Sep-09-25 11:34AM	LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal (Zacks)
08:00AM	BOTOX Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories (PR Newswire)
Sep-08-25 07:53PM	This 3 Stock Portfolio Provides Monthly Income (Zacks)
07:33PM	AbbVie (ABBV) Stock Dips While Market Gains: Key Facts (Zacks)
02:39PM	Calls of the Day: Abbvie, Vertex, Veeva and Vistra (CNBC TV)
09:42AM	Investing in Oncology: 3 Cancer Stocks With Promising Pipelines (Zacks)
09:15AM	J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned? (Zacks)
03:43AM	Loading…
03:43AM	1 Reason Every Investor Should Know About AbbVie (ABBV) (Motley Fool)
Sep-07-25 04:51AM	3 Dividend Stocks to Double Up on Right Now (Motley Fool)
Sep-06-25 06:42AM	3 Stocks to Buy and Hold Forever (Motley Fool)
Sep-05-25 09:07AM	AbbVie Declares Quarterly Dividend (PR Newswire)
Sep-04-25 09:17AM	Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth? (Zacks)
06:41AM	AbbVie and Genmabs Epkinly shows outpatient viability in Phase II trial (Clinical Trials Arena)
05:05AM	Health Canada approves AbbVies Elahere for ovarian cancer (Pharmaceutical Technology)
04:09AM	Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years? (Motley Fool)
Sep-03-25 08:30AM	AbbVie Announces Updated Results From Phase 2 EPCORE NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) (PR Newswire)
08:00AM	Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers (PR Newswire)
Sep-02-25 10:01AM	Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales (Zacks)
09:48AM	GSK Adds Around $5B in a Month: Here's How to Play the Stock (Zacks)
08:00AM	AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (PR Newswire)
03:27AM	AbbVie Inc. (ABBV) Acquires Psychedelic Drug Developer Gilgamesh for $1.2B, Enters Mental Health Market (Insider Monkey)
Sep-01-25 12:11PM	Investing in the Age of Longevity: Silver Economy Stocks in Focus (Zacks)
11:59AM	Pfizer's Golden Cross Signals Strength: How to Play the Stock (Zacks)
09:39AM	Is AbbVie Stock Underperforming the S&P 500? (Barchart)
Aug-31-25 05:41PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
04:44AM	5 High-Yield Dividend Stocks I Plan on Holding for the Next 10 Years or Longer (Motley Fool)
Aug-30-25 04:51AM	The Smartest Dividend Stocks to Buy With $500 Right Now (Motley Fool)
Aug-29-25 10:17AM	ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025? (Zacks)
09:00AM	Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know (Zacks)
07:03AM	Health Canada issues NOC to AbbVies upadacitinib for giant cell arteritis (Pharmaceutical Technology)
12:03AM	2 Reasons to Watch ABBV and 1 to Stay Cautious (StockStory)
Aug-28-25 03:32PM	These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth (Barchart)
02:41PM	Healthcare Stocks Are 'Priced at Panic Levels.' It's Time to Buy. (Barrons.com)
Aug-27-25 11:17AM	What Is the Intent Behind AbbVie's Recent Acquisition Spree? (Zacks)
Aug-26-25 09:35AM	As the Market Rotates, This Healthcare ETF Is Leading the Way (MarketBeat)
09:05AM	AbbVie's (ABBV) Fell in Line with the Broader Biopharmaceutical Industry (Insider Monkey)
08:08AM	ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression (Zacks)
07:22AM	AbbVie agrees to acquire Gilgameshs bretisilocin for $1.2bn (Pharmaceutical Technology)
04:00AM	AbbVie dives back into the neuro pool with a $1.2B psychedelics play (Pharma Voice)
Aug-25-25 10:01PM	How To Put $100 In Your Retirement Fund Each Month With AbbVie Stock (Benzinga)
07:50AM	AbbVie wagers more than $1B on Gilgameshs psychedelic drug (BioPharma Dive)
Aug-24-25 09:15AM	3 Top Stocks to Build Your Portfolio Around (Motley Fool)
Aug-23-25 06:45AM	3 Unstoppable Dividend Stocks to Buy Right Now (Motley Fool)
Aug-22-25 09:39AM	AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth (Zacks)
08:43AM	ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth (Zacks)
07:30AM	AbbVie seeks Rinvoq alopecia approval after second Phase III success (Clinical Trials Arena)
05:46AM	The Zacks Analyst Blog Highlights Alphabet, Exxon Mobil and AbbVie (Zacks)
Aug-21-25 04:36PM	AbbVie's Rinvoq Shines In Hair Loss Trial (GuruFocus.com)
04:17PM	Top Stock Reports for Alphabet, Exxon Mobil & AbbVie (Zacks)
10:10AM	AbbVie's Patch Baldness Study Finds High Hair Coverage Rates With Investigational Drug Upadacitinib (Benzinga)
08:30AM	AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ) for Alopecia Areata (PR Newswire)
07:44AM	2 High-Yield Dividend Stocks to Buy in August and Hold for a Decade or Longer (Motley Fool)
Aug-20-25 09:52AM	Does Cobenfy Have the Potential to Become a Top Drug for BMY? (Zacks)
09:40AM	AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock? (Zacks)
Aug-19-25 11:36PM	Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks (StockStory)
09:33AM	Strategic Partnerships Power Tempus AI's Healthcare Expansion (Zacks)
08:55AM	AbbVie Completes Acquisition of Capstan Therapeutics (PR Newswire)
08:00AM	SkinMedica Unveils Its Newest Hydration Hero (PR Newswire)
Aug-18-25 09:00AM	Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock (Zacks)
05:59AM	If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today (Motley Fool)
Aug-15-25 09:31PM	Marjorie Taylor Greene Keeps Buying UnitedHealth Stock Along With Fellow Investors Buffett And Burry (Benzinga)
04:53AM	3 Dividend Stocks to Double Up On Right Now (Motley Fool)
Aug-13-25 07:00AM	AbbVie to build API plant in Illinois as it steps up US production (BioPharma Dive)
05:31AM	AbbVie expands North Chicago API production with $195m investment (Pharmaceutical Technology)
12:03AM	ABBV Q2 Deep Dive: Immunology and Neuroscience Growth Outpace Aesthetics, Guidance Trimmed (StockStory)
Aug-12-25 11:50PM	5 Insightful Analyst Questions From AbbVie's Q2 Earnings Call (StockStory)
05:42PM	Stocks too expensive for your taste? This bargain-hunting strategy can yield big returns with less risk. (MarketWatch)
04:46PM	AbbVie to invest $195 million in North Chicago facility that will produce active pharmaceutical ingredients (Chicago Tribune)
01:00PM	AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S. (PR Newswire)
09:40AM	Starbucks upgraded, Shopify downgraded: Wall Street's top analyst calls (The Fly)
08:01AM	If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? (Benzinga)
06:59AM	Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda (GlobeNewswire)
05:32AM	US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche (GlobeNewswire)
Aug-11-25 12:07PM	AbbVies upadacitinib raises the bar for alopecia areata (Clinical Trials Arena)
05:38AM	Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 \| Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth (GlobeNewswire)
05:13AM	Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 \| J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations (GlobeNewswire)
Aug-10-25 10:00AM	My 3 Favorite Stocks to Buy Right Now (Motley Fool)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Richard A. Gonzalez	Former Director	Aug 22 '25	Proposed Sale	210.84	62,755	13,231,264		Aug 22 06:02 PM
Richard A. Gonzalez	Former Director	Aug 21 '25	Proposed Sale	211.04	90,000	18,993,948		Aug 21 06:04 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Option Exercise	54.86	42,370	2,324,418	219,662	Aug 14 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Sale	198.42	42,370	8,407,055	177,292	Aug 14 05:00 PM
AZITA SALEKI-GERHARDT	Officer	Aug 12 '25	Proposed Sale	198.42	42,370	8,407,068		Aug 12 07:22 PM
Richard A. Gonzalez	Former Director	Aug 01 '25	Proposed Sale	195.83	61,500	12,043,268		Aug 08 05:03 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Aug 05 '25	Sale	198.51	13,295	2,639,253	58,247	Aug 07 05:00 PM
NICHOLAS DONOGHOE	Officer	Aug 05 '25	Proposed Sale	198.51	13,299	2,639,966		Aug 05 04:40 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 31 '25	Option Exercise	79.02	25,700	2,030,814	112,066	Apr 02 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 31 '25	Sale	210.08	58,832	12,359,504	53,234	Apr 02 05:00 PM
Stewart Jeffrey Ryan	Officer	Mar 31 '25	Proposed Sale	210.09	58,832	12,359,897		Mar 31 05:30 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Mar 14 '25	Sale	212.34	17,644	3,746,527	11,577	Mar 18 05:00 PM
Reents Scott T	Officer	Mar 14 '25	Proposed Sale	212.35	17,644	3,746,628		Mar 14 04:34 PM
GONZALEZ RICHARD A	Director	Feb 28 '25	Sale	205.11	92,460	18,964,471	395,097	Mar 04 05:00 PM
GONZALEZ RICHARD A	Director	Mar 03 '25	Sale	210.53	6,168	1,298,549	388,929	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 03 '25	Option Exercise	159.88	18,008	2,879,040	22,627	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 03 '25	Sale	210.00	18,008	3,781,680	4,619	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 28 '25	Sale	206.30	9,892	2,040,722	4,619	Mar 04 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 03 '25	Sale	210.45	21,250	4,472,039	6,130	Mar 04 05:00 PM
GONZALEZ RICHARD A	Officer	Mar 03 '25	Proposed Sale	210.53	6,168	1,298,550		Mar 03 05:57 PM
PERRY C SIATIS	Officer	Mar 03 '25	Proposed Sale	210.00	18,008	3,781,680		Mar 03 04:28 PM
TIMOTHY RICHMOND	Officer	Mar 03 '25	Proposed Sale	210.46	21,250	4,472,184		Mar 03 04:08 PM
GONZALEZ RICHARD A	Officer	Feb 28 '25	Proposed Sale	205.11	92,460	18,964,882		Feb 28 05:37 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 26 '25	Option Exercise	98.48	16,260	1,601,313	28,906	Feb 28 05:00 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 26 '25	Sale	203.41	18,944	3,853,372	11,496	Feb 28 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Feb 26 '25	Option Exercise	114.36	22,210	2,539,936	66,494	Feb 28 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Feb 26 '25	Sale	202.90	29,917	6,070,036	44,284	Feb 28 05:00 PM
PERRY C SIATIS	Officer	Feb 28 '25	Proposed Sale	206.31	9,892	2,040,790		Feb 28 04:12 PM
Buckbee Kevin K	Officer	Feb 26 '25	Proposed Sale	203.41	18,944	3,853,398		Feb 26 05:47 PM
TIMOTHY RICHMOND	Officer	Feb 26 '25	Proposed Sale	202.90	29,917	6,070,176		Feb 26 04:04 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 20 '25	Sale	197.90	5,778	1,143,453	22,381	Feb 24 05:00 PM
PERRY C SIATIS	Officer	Feb 20 '25	Proposed Sale	197.90	5,778	1,143,492		Feb 20 04:10 PM
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Option Exercise	93.50	1,800	168,300	8,783	Dec 18 05:00 PM
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Sale	172.24	1,800	310,032	6,983	Dec 18 05:00 PM
Buckbee Kevin K	Officer	Dec 16 '24	Proposed Sale	172.25	1,800	310,045		Dec 16 05:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your FINVIZ experience